(Q45916179)

17 December 2017

title

Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. (English)

1 reference

17 December 2017

1 reference

5

1 reference

17 December 2017

Kai Breuhahn

6

1 reference

17 December 2017

author name string

Laura Elisa Buitrago-Molina

1

1 reference

17 December 2017

Deepika Pothiraju

2

1 reference

17 December 2017

Jutta Lamlé

3

1 reference

17 December 2017

Silke Marhenke

4

1 reference

17 December 2017

Michael P Manns

7

1 reference

17 December 2017

Nisar Malek

8

1 reference

17 December 2017

Arndt Vogel

9

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

17 December 2017

published in

Hepatology

1 reference

17 December 2017

volume

50

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

500-509

1 reference

17 December 2017

Defining the role of mTOR in cancer

cites work

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

21 January 2018

1 reference

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

The pathophysiology and treatment of hereditary tyrosinemia type 1.

21 January 2018

1 reference

NTBC treatment in tyrosinaemia type I: long-term outcome in French patients

21 January 2018

1 reference

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.

21 January 2018

1 reference

Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.

21 January 2018

1 reference

Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.

21 January 2018

1 reference

Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.

21 January 2018

1 reference

Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis

21 January 2018

1 reference

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.

21 January 2018

1 reference

Ribosomal protein S6 phosphorylation and function during late gestation liver development in the rat

21 January 2018

1 reference

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells

21 January 2018

1 reference

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

21 January 2018

1 reference

Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation

21 January 2018

1 reference

Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes

21 January 2018

1 reference

Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.23014

1 reference

17 December 2017

1 reference

17 December 2017